Search Results

You are looking at 101 - 110 of 177 items for :

  • "cetuximab" x
  • All content x
Clear All
Full access

Mario E. Lacouture

this rash. Minocycline 100 mg per day was shown to reduce lesions by more than 50% and rash severity within the first 4 weeks of treatment with cetuximab. 2 Similarly, 150 mg of minocycline twice per day on day 1 of treatment with erlotinib reduced

Full access

Ronan J. Kelly

bevacizumab has limited activity in thymic malignancies. Cetuximab has been reported to have some activity, although these data are from 2 single case reports in which 1 patient overexpressed EGFR on immunohistochemistry and the other did not. 30 , 31 A phase

Full access

Harold J. Burstein

constitute what most observers would consider appropriate use. The 10 drugs in this analysis (albumin-bound paclitaxel, azacytidine, bevacizumab, bortezomib, cetuximab, docetaxel, gemcitabine, pemetrexed, rituximab, and trastuzumab) are products well

Full access

Francis P. Worden and Huan Ha

. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck . N Engl J Med 2006 ; 354 : 567 – 578 . 31. Mell LK Weichselbaum RR . More on cetuximab in head and neck cancer . N Engl J Med 2007 ; 357 : 2201 – 2202 ; author

Full access

Kamel Izeradjene and Sunil R. Hingorani

B . Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody . Drugs Today (Barc) 2005 ; 41 : 107 – 127 . 36. Sclabas GM Fujioka S Schmidt C . Restoring apoptosis in pancreatic cancer cells by targeting

Full access

Lainie Martin and Russell J. Schilder

. Hunter T . Signaling—2000 and beyond . Cell 2000 ; 100 : 113 – 127 . 4. Blume-Jensen P Hunter T . Oncogenic kinase signalling . Nature 2001 ; 411 : 355 – 365 . 5. Cunningham D Humblet Y Siena S . Cetuximab monotherapy and

Full access

Vaia Florou, Christopher Nevala-Plagemann, Jonathan Whisenant, Patricia Maeda, Glynn W. Gilcrease, and Ignacio Garrido-Laguna

feedback activation of EGFR . Nature 2012 ; 483 : 100 – 103 . 10.1038/nature10868 22281684 26. Kopetz S , Grothey A , Yaeger R , Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer . N Engl J Med 2019 ; 381

Full access

David Adelstein, Maura L. Gillison, David G. Pfister, Sharon Spencer, Douglas Adkins, David M. Brizel, Barbara Burtness, Paul M. Busse, Jimmy J. Caudell, Anthony J. Cmelak, A. Dimitrios Colevas, David W. Eisele, Moon Fenton, Robert L. Foote, Jill Gilbert, Robert I. Haddad, Wesley L. Hicks Jr, Ying J. Hitchcock, Antonio Jimeno, Debra Leizman, William M. Lydiatt, Ellie Maghami, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, James Rocco, Cristina P. Rodriguez, Jatin P. Shah, Randal S. Weber, Matthew Witek, Frank Worden, Sue S. Yom, Weining Zhen, Jennifer L. Burns, and Susan D. Darlow

using immunotherapy and targeted therapy agents such as cetuximab. 42 , 43 , 50 The ECOG-ACRIN phase II E1308 trial, in which patients with stage III–IV HPV16 and/or p16-positive oropharyngeal cancer (N=80) received induction chemotherapy followed by

Full access

Metastatic Colon Cancer, Version 3.2013

Featured Updates to the NCCN Guidelines

Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass

combination or as single agents, given across a continuum: 5-FU/LV, capecitabine, irinotecan, oxaliplatin, bevacizumab, cetuximab, panitumumab, ziv-aflibercept, and regorafenib. 22 - 62 The putative mechanisms of action of these agents are varied and include

Full access

Ajeet Gajra, Alissa S. Marr, and Apar Kishor Ganti

-year survival rates were similar in the 2 arms (7.9 months and 31% for paclitaxel poliglumex arm vs 8.0 months and 31% for the standard arm). CALGB 30402 was a randomized phase II trial that compared docetaxel-bortezomib and docetaxel-cetuximab in